Action MRYp MIRA IV ACQUISITION CORP
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Mira IV Acquisition Corp Toronto S.E.

Actions

MRYp

CA60456Q1054

Cours en clôture Toronto S.E.
Autres places de cotation
- - Graphique intraday de Mira IV Acquisition Corp
15/05 Transcript : Profound Medical Corp. - Shareholder/Analyst Call
14/05 Le secteur des soins de santé est stable en début de marché MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
PROFOUND MEDICAL ANNUAL GENERAL MEETING OF SHAREHOLDERS VOTING RESULTS
Sector Update: Health Care Stocks Steady Premarket Tuesday
Profound Medical Receives FDA Approval for AI-Powered Prostate Disease Device --Shares Advance Pre-Bell
Profound Medical Receives U.S. FDA Clearance for "Contouring Assistant" AI Module
Profound Medical Brief: Says Received U.S. FDA 510(k) Clearance for 'Contouring Assistant' AI Module that Enables Creation of an Automated TULSA Treatment Plan
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
Profound Medical Receives U.S. FDA 510(K) Clearance for Contour Assistant AI Module That Enables Creation of an Automated Tulsa Treatment Plan
Profound Reports a Narrower First-Quarter Loss; Provides 2024 Revenue Guidance
Profound Medical Brief: Expects total revenue for FY24 to be in the range of US$11.0-$12.0 million, which represents 53% to 67% growth compared to its prior year revenue
Profound Medical Brief: Recorded Q1 revenue of approximately $1.91 million, with $1.48 million from recurring revenue; Issues Full-Year 2024 Revenue Guidance
Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance
Profound Medical Corp. Provides Earnings Guidance for Full-Year 2024
Profound Medical Says Clinical Evidence Points to Potential of Its TULSA Procedure as a Treatment for Prostate Cancer
Profound Medical Brief: Adds Clinical evidence Continues to highlight TULSA's "Ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH"
Profound Medical Brief: Says "Growing Body of Clinical Evidence" Points to Potential of Its TULSA Procedure "Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum"
Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Profound Medical Reports Q4 Net Loss of US$0.42 Per Share, Announces COO Appointment
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PRN
  4. Action MRYp
  5. Actualités Mira IV Acquisition Corp
  6. Autres langues